Treatment of patients infected with chronic hepatitis C genotype 2 and 3: More data, more questions?

Alessandra Mangia, Rosanna Santoro, Nicola Minerva, Giovanni L. Ricci, Vito Carretta, Marcello Persico, Francesco Vinelli, Gaetano Scotto, Donato Bacca, Mauro Annese, Mario Romano, Franco Zechini, Fernando Sogari, Fulvio Spirito, Angelo Andriulli, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. The New England Journal of Medicine. ,vol. 352, pp. 2609- 2617 ,(2005) , 10.1056/NEJMOA042608

Jules L. Dienstag, J.G. McHutchison, American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. ,vol. 130, pp. 225- 230 ,(2006) , 10.1053/J.GASTRO.2005.11.011

Michael von Wagner, Miriam Huber, Thomas Berg, Holger Hinrichsen, Jens Rasenack, Tobias Heintges, Alexandra Bergk, Christine Bernsmeier, Dieter Häussinger, Eva Herrmann, Stefan Zeuzem, Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C Gastroenterology. ,vol. 129, pp. 522- 527 ,(2005) , 10.1053/J.GASTRO.2005.05.008

Mitchell L Shiffman, Marc G Ghany, Timothy R Morgan, Elizabeth C Wright, Gregory T Everson, Karen L Lindsay, Anna SF Lok, Herbert L Bonkovsky, Adrian M Di Bisceglie, William M Lee, Jules L Dienstag, David R Gretch, HALT-C Trial Group, None, Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C Gastroenterology. ,vol. 132, pp. 103- 112 ,(2007) , 10.1053/J.GASTRO.2006.11.011

Michael W. Fried, Mitchell L. Shiffman, K. Rajender Reddy, Coleman Smith, George Marinos, Fernando L. Gonçales, Dieter Häussinger, Moises Diago, Giampiero Carosi, Daniel Dhumeaux, Antonio Craxi, Amy Lin, Joseph Hoffman, Jian Yu, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine. ,vol. 347, pp. 975- 982 ,(2002) , 10.1056/NEJMOA020047

Ira M Jacobson, Robert S Brown Jr, Bradley Freilich, Nezam Afdhal, Paul Y Kwo, John Santoro, Scott Becker, Adil E Wakil, David Pound, Eliot Godofsky, Robert Strauss, David Bernstein, Steven Flamm, Mary Pat Pauly, Pabak Mukhopadhyay, Louis H Griffel, Clifford A Brass, None, Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial Hepatology. ,vol. 46, pp. 971- 981 ,(2007) , 10.1002/HEP.21932

Martin Lagging, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Amar P. Dhillon, Åsa Alsiö, Kristoffer Hellstrand, Johan Westin, Gunnar Norkrans, , Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. ,vol. 47, pp. 1837- 1845 ,(2008) , 10.1002/HEP.22253

Doris B. Strader, Teresa Wright, David L. Thomas, Leonard B. Seeff, Diagnosis, Management, and Treatment of Hepatitis C Hepatology. ,vol. 39, pp. 1147- 1171 ,(2004) , 10.1002/HEP.20119

Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, Ernesto Agostinacchio, Fernando Sogari, Gaetano Scotto, Francesco Vinelli, Giovanni Luciano Ricci, Mario Romano, Vito Carretta, Daniela Petruzzellis, Angelo Andriulli, Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. ,vol. 49, pp. 358- 363 ,(2009) , 10.1002/HEP.22679

Olav Dalgard, Kristian Bjøro, Helmer Ring-Larsen, Einar Bjornsson, Mona Holberg-Petersen, Eva Skovlund, Olle Reichard, Bjørn Myrvang, Bo Sundelöf, Ståle Ritland, Kjell Hellum, Aril Frydén, Jon Florholmen, Hans Verbaan, Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. ,vol. 47, pp. 35- 42 ,(2007) , 10.1002/HEP.21975